Skip to main content

Table 1 Demographics and clinical characteristics of the subgroup according to early neurological outcomes

From: The association of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and lymphocyte to monocyte ratio with post-thrombolysis early neurological outcomes in patients with acute ischemic stroke

Variable END group (n = 193) Neither END nor ENI group (n = 469) ENI group (n = 398) P
Demographic characteristics
 Age, years 73.2 ± 11.5 69.6 ± 12.0 a 68.1 ± 12.1 b 0.001
 Male, n (%) 121 (62.7) 319 (68.0) 260 (65.3) 0.303
 BMI, kg/m2 24.4 ± 3.6 24.1 ± 3.5 23.9 ± 3.6 0.242
Vascular risk factors, n (%)
 Hypertension 132 (68.4) 315 (67.2) 275 (69.1) 0.816
 Diabetes mellitus 51 (26.4) 116 (24.7) 77 (19.3) b 0.079
 Dyslipidemia 51 (26.4) 120 (25.6) 114 (28.6) 0.592
 Atrial fibrillation 49 (25.4) 96 (20.5) 75 (18.8) 0.180
 Current smoking 59 (30.6) 149 (31.8) 129 (32.4) 0.903
 Current drinking 69 (35.8) 145 (30.9) 129 (32.4) 0.482
 Previous stroke 38 (19.7) 114 (24.3) 80 (20.1) 0.238
 Peripheral artery disease 11 (5.7) 30 (6.4) 30 (7.5) 0.662
 Coronary artery disease 38 (19.7) 83 (17.7) 81 (20.4) 0.603
Medication use history, n (%)
 Previous antiplatelet 21 (10.9) 88 (18.8) a 91 (22.9) b 0.002
 Previous statin 15 (7.8) 49 (10.4) 42 (10.6) 0.521
 Previous anticoagulation 5 (2.6) 11 (2.3) 5 (1.3) 0.391
Clinical assessment
 NIHSS, score 11 (5, 17) 5 (3, 12) a 8 (4, 14) b,c 0.001
 SBP, mmHg 146.9 ± 23.6 151.8 ± 25.7 148.3 ± 22.6 0.171
 DBP, mmHg 87.8 ± 16.2 89.4 ± 14.4 86.8 ± 14.6 c 0.034
 HT, n (%) 32 (16.6) 37 (7.9) a 13 (3.3) b,c 0.001
 OTT, minute 165.00 (120.00, 200.00) 160.00 (115.00, 200.00) 130.00 (90.00, 180.00) b,c 0.001
 PAO, n (%) 77 (39.9) 134 (28.6) a 91 (22.9) b 0.001
 Endovascular treatment, n (%) 43 (22.3) 77 (16.4) 65 (16.3) 0.148
Stroke subtype, n (%) 0.001
 LAA 73 (37.8) 169 (36.0) 147 (36.9)  
 CE 62 (32.1) 120 (25.6) 132 (33.2)  
 SAO 27 (14.0) 138 (29.4) a 83 (20.9)  
 SOE 8 (4.1) 16 (3.4) 8 (2.0)  
 SUE 23 (12.0) 26 (5.6) a 28 (7.0)  
Lesion location, n (%) 0.616
 Anterior circulation 149 (77.2) 357 (76.1) 294 (73.9)  
 Posterior circulation 44 (22.8) 112 (23.9) 104 (26.1)  
Laboratory data
 TC, mmol/L 4.41 ± 1.11 4.38 ± 1.11 4.32 ± 1.10 0.591
 TG, mmol/L 1.14 (0.82, 1.68) 1.19 (0.86, 1.70) 1.20 (0.85, 1.75) 0.744
 HDL, mmol/L 1.21 ± 0.68 1.14 ± 0.36 1.13 ± 0.49 0.214
 LDL, mmol/L 2.53 (1.95, 3.20) 2.63 (1.98, 3.23) 2.59 (1.96, 3.27) 0.733
 FBG, mmol/L 7.30 ± 2.95 6.28 ± 2.47 a 6.86 ± 3.19 c 0.001
 Hs-CRP, mg/L 7.25 (2.66, 14.55) 4.28 (2.11, 7.55) a 4.85 (2.16, 8.61) b 0.001
 NLR 6.09 (4.43, 8.02) 4.15 (3.14, 5.26) a 3.17 (2.54, 4.22) b,c 0.001
 PLR 179.1 (122.1, 251.1) 126.7 (98.8, 158.0) a 133.1 (102.5, 168.2) b 0.001
 LMR 3.03 (2.50, 4.13) 3.36 (2.48, 4.34) 3.63 (2.61, 4.52) b 0.014
  1. Abbreviations: END early neurological deterioration, ENI, early neurological improvement, BMI body mass index, NIHSS National Institute of Health Stroke Scale, SBP systolic blood pressure, DBP diastolic blood pressure, HT hemorrhagic transformation, OTT onset to treatment time, PAO proximal arterial occlusion, LAA large-artery atherosclerosis, CE cardioembolism, SAO small-artery occlusion, SOE stroke of other determined etiology, SUE stroke of undetermined etiology, TC total cholesterol, TG triglyceride, LDL low-density lipoprotein, HDL high-density lipoprotein, FBG fasting blood glucose, Hs-CRP hyper-sensitive C-reactive protein, NLR neutrophil-lymphocyte ratio, PLR platelet-lymphocyte ratio, LMR lymphocyte-monocyte ratio
  2. aThis variable is different significantly between END group and neither END nor ENI group, P < 0.05
  3. bThis variable is different significantly between ENI group and END group, P < 0.05
  4. cThis variable is different significantly between neither END nor ENI group and ENI group, P < 0.05